When “No Human Trials” Really Means “No One Paid for Them”
One of the most overused phrases in health care is: “There’s no evidence.”
Sometimes that is true.
But sometimes what people really mean is: “There isn’t a large randomized human trial.”
Those are not the same thing.
A therapy can have a plausible mechanism, years of laboratory research, peer-reviewed animal studies, and substantial anecdotal experience—and still have very little high-quality human research.
That should make us cautious. It should not automatically make us dismissive.
The more interesting question isn’t always, “Why isn’t there evidence?” Sometimes the better question is, “Why was the human research never funded?”
Peer Reviewed Does Not Mean “Proven”
First, we need to get our terminology straight.
Peer reviewed describes how research was evaluated before publication. It does not automatically tell you how strong the evidence is.
A laboratory experiment can be peer reviewed. A mouse study can be peer reviewed. A case report can be peer reviewed. A randomized controlled trial can be peer reviewed.
Those studies do not carry the same evidentiary weight.
Anecdotal Evidence
Real-world observations that can identify signals and generate questions—but cannot establish cause and effect.
Laboratory Research
Helps identify mechanisms and biological plausibility under controlled experimental conditions.
Animal Research
Allows researchers to study whole-body biological effects before moving into human trials.
Human Clinical Trials
Needed to determine whether a therapy is actually safe and effective in people.
Evidence Exists on a Spectrum
If researchers give a peptide to injured rats and the animals recover faster, that is evidence. It is simply not the same level of evidence as a controlled human trial.
Anecdotes Aren’t Proof. They Aren’t Worthless Either.
Anecdotal experience has obvious limitations.
People know what they took. Expectations affect perception. Symptoms fluctuate. Injuries naturally heal. People often change several variables at once. Positive experiences are also more likely to be repeated than neutral ones.
That is exactly why controlled trials exist.
But if hundreds or thousands of people consistently report the same observation, I don’t think the scientifically appropriate response is:
Wrong Extreme #1
“People say it works, therefore it is proven.”
Wrong Extreme #2
“There isn’t a Phase 3 trial, therefore the observation means nothing.”
Interesting observations should create questions. Good science should then attempt to answer them.
Somebody Has to Pay for the Trial
Large human clinical trials are extraordinarily expensive.
Drug development may involve laboratory research, manufacturing, toxicology, pharmacokinetics, regulatory filings, Phase 1 testing, Phase 2 trials, Phase 3 trials, monitoring, data analysis, and ultimately regulatory review.
Somebody has to pay for all of that.
And Funding Usually Requires an Economic Reason
Pharmaceutical research and development is strongly influenced by expected revenue, development cost, probability of success, market size, patent protection, and regulatory exclusivity.
What Happens When the Molecule Is Harder to Own?
You will sometimes hear people say: “Peptides can’t be patented.”
That statement is too broad.
Novel peptide analogues, new formulations, delivery systems, manufacturing methods, and new therapeutic applications may potentially receive intellectual-property protection.
But naturally occurring molecules, older compounds, and molecules already described in the scientific literature may have a weaker intellectual-property position than a completely novel pharmaceutical compound.
And weaker exclusivity can mean weaker financial incentive to spend enormous amounts of money proving that molecule works.
The research pipeline has an economic filter.
Promising biology does not automatically become a billion-dollar clinical program.That Doesn’t Prove a Conspiracy
It demonstrates something far more ordinary: companies generally invest where they believe there is a reasonable opportunity for return on investment.
And Yet Some of the Animal Research Is Hard to Ignore
BPC-157
Experimental tendon research has reported effects involving fibroblast migration, cellular survival, and tissue-repair signaling.
Rat tendon studies provide legitimate biological reasons for continued investigation.
They do not prove that injectable BPC-157 heals human orthopedic injuries.
MOTS-c
A 2015 study reported that MOTS-c administration in mice protected against age-dependent and high-fat-diet-induced insulin resistance.
Researchers also observed effects involving metabolism and diet-induced obesity.
Again—interesting animal biology, not proof of equivalent human outcomes.
SS-31
Researchers treated old mice with SS-31 for eight weeks and reported improvements in age-related cardiac dysfunction, exercise capacity, mitochondrial proton leak, and oxidative stress.
That is compelling preclinical research.
The words “in old mice” still matter.
Sometimes the Animal Research Eventually Becomes Medicine
SS-31 did not remain an interesting mitochondrial peptide confined to laboratory research.
It was developed clinically as elamipretide.
In September 2025, the FDA granted accelerated approval to Forzinity™ for a specific indication in patients with Barth syndrome.
That does not validate every proposed wellness or longevity use of SS-31.
But it illustrates an important point:
Preclinical Research Can Matter
Sometimes fascinating animal or laboratory findings eventually move through years of development and become legitimate human medicine.
So Does Positive Animal Research Mean We Should Use Something?
Mice are not small humans.
Doses do not always translate cleanly. Pharmacokinetics differ. Disease models are imperfect. Manufacturing quality matters. Long-term human safety may be completely unknown.
An impressive effect in a laboratory can disappear when tested in a diverse human population.
Promising is not proven. But promising is not meaningless either.
What About “Peptides vs. Drugs”?
Peptides are sometimes discussed as though they are fundamentally different from drugs.
Pharmacologically, that isn’t accurate.
A peptide can absolutely be a drug.
Insulin is peptide-based. GLP-1 receptor agonists are peptide therapeutics. Bremelanotide is a peptide drug. Elamipretide is now an FDA-approved peptide drug.
What is interesting is that some experimental peptide approaches are discussed as short courses, cycles, recovery tools, or as-needed interventions rather than medications intended to be taken indefinitely.
But That Does Not Apply to Every Peptide
Some peptide medications are used chronically. Some conventional medications are used temporarily. The molecule and clinical problem determine the treatment strategy—not whether something carries the label “peptide.”
Does Conventional Medicine Depend on Keeping People on Drugs?
Chronic therapy is obviously an attractive business model.
A medication taken every day for years creates recurring revenue. Add patent protection and regulatory exclusivity, and the economics become even more attractive.
But it would be inaccurate to say that conventional drugs are universally designed to lose effectiveness so patients continually need larger doses.
Tolerance does occur with certain drugs and certain biological pathways. It does not happen with every medication.
And many people remain on medication because the underlying disease is chronic—not because the medicine intentionally created dependence.
The More Defensible Criticism Is Also the More Interesting One
Our pharmaceutical-development system naturally directs capital toward therapies that can generate enough revenue to justify the cost and risk of development.
That means the compounds receiving the largest clinical trials are not necessarily the only biologically interesting compounds.
Follow the Evidence—But Also Follow the Incentives
I don’t want to live at either extreme.
I don’t believe:
“It’s peer reviewed, therefore it must be true.”
I don’t believe:
“People online say it works, therefore it must work.”
And I don’t believe:
“There isn’t an FDA-approved indication, therefore there is no interesting science here.”
I want better questions.
The Uncomfortable Middle Ground
Sometimes the difference between “promising experimental therapy” and “evidence-based medicine” is not that one molecule has fascinating biology and the other doesn’t.
Sometimes one of them had someone willing to spend the money required to prove it.
That doesn’t mean we lower our scientific standards.
It means we understand how the scientific system actually works.
Scientific Skepticism Should Work in Both Directions
We should be skeptical when someone claims an experimental therapy is proven because it worked in mice.
We should also be skeptical when someone claims there is “no evidence” simply because nobody has spent the money required to run a large human trial.
Ask what we know. Ask what we don’t know. Then ask who had an incentive to find out.About the Author
Selected Sources
Research and Development in the Pharmaceutical Industry — discussion of expected revenue, development cost, market exclusivity, and pharmaceutical R&D incentives.
View CBO Report →
Patent subject-matter eligibility guidance, including naturally occurring products and patentable inventions.
View USPTO Information →
Experimental research examining BPC-157 and tendon fibroblast migration, survival, and repair-related biology.
View on PubMed →
MOTS-c research involving metabolic homeostasis, insulin resistance, and diet-induced obesity in mice.
View on PubMed →
Eight-week SS-31 research examining age-related cardiac dysfunction, mitochondrial proton leak, oxidative stress, and exercise performance in old mice.
View Study →
FDA accelerated approval of Forzinity™ (elamipretide) for a specific indication in Barth syndrome.
View FDA Approval →